All Articles

With 61% of its students being the first in their families to attend college, Goodwin's new initiatives offer more than support—they offer a national blueprint.

With an oversubscribed $130M Series B, Crystalys Therapeutics is accelerating its gout drug, dotinurad. But can it win the race to serve millions?

By appointing its first Chief People Officer from the world of high-growth retail, Spear Therapy is betting that employee experience is the key to scaling patient care. Here’s the strategic rationale.

Stearns & Foster, a brand synonymous with handcrafted luxury since 1846, is betting its future on a fusion of heritage and science. Is this the answer to our sleep crisis?

As Frontier prepares its Q2 results, a strategic shift is underway. Can First Class seats and Wi-Fi coexist with an ultra-low-cost model? All eyes are on ULCC.

A new partnership between Evogene and ELEO leverages AI and natural product science to create an oral PCSK9 inhibitor, aiming to disrupt a $23B market.

As ACCO Brands preps its Q2 report, investors seek clues on hybrid work, gaming, and back-to-school trends. Can strategic acquisitions offset economic headwinds?

A new alliance between Pentera and Recorded Future bridges the critical gap between threat intelligence and security validation, turning data into defense.

When a hospital's diagnostic system fails, the cost is human. A $2.1M verdict reveals how a breakdown in this invisible network led to a preventable death.

As TuHURA Biosciences takes the stage at a key investor conference, its multi-pronged attack on immunotherapy resistance faces a critical test.

As Premium Brands preps its Q2 results, investors are watching if its U.S. acquisition strategy can offset seafood struggles and inflationary pressures.

With $8M in new funding, Tikva Allocell is advancing a novel cell therapy that uses armored, virus-specific T cells to overcome historical barriers in cancer.

Marquis MD's new concierge clinic promises a cure for healthcare's frustrations. But as it caters to the elite, does it widen the care gap for everyone else?

With a veteran team from Meta and Snowflake and a massive $180M war chest, Glow is betting it can win the AI security arms race with a radical new model.

With UK approval for its FLAMINGO-01 trial, Greenwich LifeSciences partners with a top cancer center, signaling a key move in the race to prevent breast cancer recurrence.

How CSTS and Connexus navigated a tri-nation World Cup to achieve record sales, signaling a new era for premium sports tourism in Greater China.

In a decisive strategic pivot, MAS and SPARC divested its medical staffing unit to focus on the booming home and community-based care sectors. Why?

While others chase fleeting trends, EMERGE Commerce builds a durable portfolio. A deep dive into how its niche strategy is redefining success in e-commerce.

Science Corp.'s PRIMA device is a medical miracle, restoring sight to those with AMD. But can this BCI breakthrough navigate Europe's complex market hurdles?

With the hire of AI pioneer Dan Hinckley, rapidly growing Herringbone signals a move beyond acquisition, betting its future on a unified AI-driven platform.